249 - Intricacies of CMV: Treatment and Prophylaxis Challenges

Saturday, October 19, 2024

1:45 PM – 3:00 PM US PT

Location: Concourse 151

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Christine Johnston, MD, MPH (she/her/hers)

Associate Professor
Medicine
University of Washington
Seattle, WA, United States
Guy Handley, MD

Assistant Professor
Department of Medicine, Division of Infectious Disease and International Medicine, Morsani College of Medicine, University of South Florida
University of South Florida
Tampa, FL, United States

Faculty(s)

Hannah Imlay, MD, MS (she/her/hers)

Associate professor
Division of Infectious Diseases
University of Utah Health
Salt Lake City, UT, United States
Joseph Sassine, MD

Assistant Professor of Medicine
Infectious Diseases Section
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Soren Gantt, MD PhD MPH

Professor, Departments of Microbiology and Pediatrics
University of Montreal / Sainte-Justine University Hospital Centre

Disclosure(s):

Christine Johnston, MD, MPH: Assembly Bioscience: Advisor/Consultant (Ongoing); Gilead Biosciences: Grant/Research Support (Terminated, December 31, 2022); GSK: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Moderna, Inc.: Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing)

Hannah Imlay, MD, MS: No financial relationships to disclose

Joseph Sassine, MD: Ansun BioPharma: Grant/Research Support (); Cidara Therapeutics: Grant/Research Support (); Community Infusion Solutions: Grant/Research Support (); F2G: Grant/Research Support (); Shionogi: Grant/Research Support ()

Soren Gantt, MD PhD MPH: Altona Diagnostics: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); CSL Seqirus Inc.: Advisor/Consultant (Terminated); Curevo Vaccines: Advisor/Consultant (Ongoing); GSK: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Moderna Therapeutics: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Grant/Research Support (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe advances in cmv prevention for stem cell and solid organ transplant population;
identify strategies to manage refractory cmv infection;
explain the impact of congenital cmv infection and identify prevention strategies in pregnant people and neonates.

Presentations:

1:45 PM – 2:10 PM US PT

Progress and Opportunities: CMV Prevention
Speaker: Hannah Imlay, MD, MS (she/her/hers) – University of Utah Health
2:10 PM – 2:35 PM US PT

Treating refractory CMV in difficult cases
Speaker: Joseph Sassine, MD – University of Oklahoma Health Sciences Center
2:35 PM – 3:00 PM US PT

Congenital CMV: A rapidly changing field
Speaker: Soren Gantt, MD PhD MPH – University of Montreal / Sainte-Justine University Hospital Centre